



UroGen Pharma to Participate in the B. Riley Healthcare Conference

January 11, 2024

- Fireside Chat January 18, 2024, at 12:00 pm ET -

PRINCETON, N.J.--(BUSINESS WIRE)--Jan. 11, 2024-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that Liz Barrett, President and CEO, will participate in a fireside chat at the upcoming B. Riley Virtual Healthcare Conference on January 18th beginning at 12:00 p.m. ET.

To access the event, please RSVP to your B. Riley Securities sales representative. Following the event, a replay of the fireside chat will be available at the "[Events and Presentations](#)" section of UroGen's investor website for approximately 30 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Jelmyto® (mitomycin) for pyelocaliceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240111451437/en/): <https://www.businesswire.com/news/home/20240111451437/en/>

INVESTOR CONTACT:

Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588

MEDIA CONTACT:

Cindy Romano
Director, Communications
cindy.romano@urogen.com
908-963-7827

Source: UroGen Pharma Ltd.